{"id":95447,"date":"2021-07-28T19:13:00","date_gmt":"2021-07-28T09:13:00","guid":{"rendered":"https:\/\/www.fnarena.com\/index.php\/2021\/07\/28\/eccogene-announces-completed-first-in-human-of-ecc0509-in-phase-1a-clinical-trial-in-australia\/"},"modified":"2021-07-28T19:13:00","modified_gmt":"2021-07-28T09:13:00","slug":"eccogene-announces-completed-first-in-human-of-ecc0509-in-phase-1a-clinical-trial-in-australia","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2021\/07\/28\/eccogene-announces-completed-first-in-human-of-ecc0509-in-phase-1a-clinical-trial-in-australia\/","title":{"rendered":"Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SHANGHAI<\/span>, July 28, 2021<\/span> \/PRNewswire\/ — Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-sensitive amine oxidase (SSAO)\/vascular adhesion protein-1 (VAP-1), as a potentially novel therapy for patients with non-alcoholic steatohepatitis (NASH) and osteoarthritis (OA) associated pain. <\/p>\n

\n<\/p><\/div>\n

The trial is a Phase 1, randomized, double-blind, placebo-controlled, sequential single- and multiple ascending dose clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics of ECC0509 in healthy volunteers. All participants will receive either placebo, or a single dose or multiple doses of ECC0509. Preliminary topline data from the clinical trial is expected in Q1 2022. <\/p>\n

About ECC0509<\/b><\/p>\n

ECC0509 is a highly selective and peripherally distributed small molecule inhibitor of SSAO\/VAP-1, elevated activity of which is associated with pathophysiology of human disorders including NASH and OA. In Eccogene non-clinical studies, ECC0509 was shown to be well-absorbed, safe at the anticipated human dose range, and efficacious in animal models of NASH and OA pain following oral administration. <\/p>\n

About Eccogene<\/b><\/p>\n

Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases.<\/p>\n

Contacts for Eccogene
<\/b>contact@eccogene.com<\/a>
www.eccogene.com<\/a><\/p>\n

 <\/p>\n

 <\/p>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SHANGHAI, July 28, 2021 \/PRNewswire\/ — Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/95447"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=95447"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/95447\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=95447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=95447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=95447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}